We look forward to further evaluating RAIN-32 both in liposarcoma, as well as in other solid tumor indications characterized by MDM2 gene amplification with this dosing regimen.”The Phase 1 dose ...

“An intermittent dosing schedule (260 mg qd, 3/14 days) of our highly selective inhibitor of the p53-MDM2 complex, milademetan, resulted in favorable safety and clinical activity in the Phase 1 ...